Pembrolizumab + 177Lu-PSMA-617
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Castrate Resistant Prostate Cancer
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Trial Timeline
Dec 15, 2023 → May 31, 2031
NCT ID
NCT05766371About Pembrolizumab + 177Lu-PSMA-617
Pembrolizumab + 177Lu-PSMA-617 is a phase 2 stage product being developed by Merck for Castrate Resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05766371. Target conditions include Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer.
What happened to similar drugs?
1 of 4 similar drugs in Castrate Resistant Prostate Cancer were approved
Approved (1) Terminated (1) Active (2)
❌custirsen sodium + isotonic, 0.9% sodium chloride + docetaxel + cabazitaxel + prednisoneAchieve Life SciencesPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05766371 | Phase 2 | Recruiting |
Competing Products
20 competing products in Castrate Resistant Prostate Cancer